ATHERSYS, INC. (NASDAQ:ATHX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Athersys, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June18, 2018. Set forth below are the voting results for each of the matters submitted to a vote of the Company’s stockholders at the Annual Meeting.
Proposal One – Election of Directors.
All nominees for election to the Company’s Board of Directors named in the Company’s proxy statement filed with the Securities and Exchange Commission on April26, 2018 were elected, each to a one-year term, with the following vote:
|
Shares Voted For |
Shares Withheld |
Broker Non-Votes |
|
| Gil Van Bokkelen | 44,623,433 | 1,159,244 | 78,148,274 |
| John J. Harrington | 42,857,393 | 2,925,284 | 78,148,274 |
| Lee E. Babiss | 39,043,466 | 6,739,211 | 78,148,274 |
| Ismail Kola | 40,822,678 | 4,959,999 | 78,148,274 |
| Lorin J. Randall | 40,210,658 | 5,572,019 | 78,148,274 |
| Jack L. Wyszomierski | 40,807,175 | 4,975,502 | 78,148,274 |
| Hardy TS Kagimoto | 42,656,751 | 3,125,926 | 78,148,274 |
Proposal Two – Ratification of the Appointment of the Company’s Independent Auditors.
The Company’s stockholders ratified the appointment of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018 with the following vote:
|
For |
Against |
Abstain |
| 122,530,888 | 1,252,797 | 147,266 |
Proposal Three – Advisory Vote on Named Executive Officer Compensation.
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers with the following vote:
|
For |
Against |
Abstain |
Broker Non-Votes |
| 41,930,751 | 3,379,953 | 471,973 | 78,148,274 |
About ATHERSYS, INC. (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
